IMNM Share Price Performance
US$23.48
11.46 (95.34%)
Price US$23.48
Share Pricen/a
Immunome, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
IMNM Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Immunome, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -2.43
- -1,701.90%
- -2,301.30%
- 0%
About IMNM
- Founded
- 2006
- Employees
- 168
- CEO
- WebsiteView website
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company’s clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
